Testosterone enanthate

CAS No. : 315-37-7

Testosterone enanthate,315-37-7
Product Details
Cat No:R065024
Synonyms:(17β)-17-[(1-Oxoheptyl)oxy]androst-4-en-3-one, 17β-Hydroxy-4-androsten-3-one 17-enanthate, 4-Androsten-17β-ol-3-one 17-enanthate, NSC 17591, Testosterone 17β-heptanoate
Molecular Formula:C26H40O3
Molecular Weight:400.603
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

Appearance: Powder
Purity: 98.0%
Cat No:R065024
Cas No:315-37-7
Product-Name:Testosterone enanthate
IUPAC Name:[(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] heptanoate
Drug Control: USDEA Schedule III; Home Office Schedule 4.2; regulated under CDSA
Testosterone Enanthate is a single large ester base testosterone compound. This is a pure synthetic testosterone hormone that has a carboxylic acid ester attached in Enanthate (enanthoic acid). The ester itself is attached to the hormone at the 17-beta hydroxyl group. By attaching the Enanthate ester, this allows for a control of the hormones active duration and total release time. Once injected, the testosterone does not become active until the ester begins to detach from the hormone. The total detachment does not happen all at once but allows for a slow, steady release of the active hormone into the body. Once injected, there will be a sharp spike in testosterone within the first 24-48 hours post injection. From here the hormone will continually separate and dissipate through the body. By its time frame, Testosterone Enanthate carries a half-life of approximately 8 days, which will allow for as little as one injection every 2 weeks in a therapeutic setting. However, every 7-10 days will prove far more effective in maintaining stability.
1: Sadowska-Krępa E, Kłapcińska B, Jagsz S, Nowara A, Szołtysek-Bołdys I, Chalimoniuk M, Langfort J, Chrapusta SJ. High-dose testosterone enanthate supplementation boosts oxidative stress, but exerts little effect on the antioxidant barrier in sedentary adolescent male rat liver. Pharmacol Rep. 2017 Mar 11;69(4):673-678. doi: 10.1016/j.pharep.2017.02.023. [Epub ahead of print] PubMed PMID: 28531762.
2: Joksimović J, Selaković D, Jakovljević V, Mihailović V, Katanić J, Boroja T, Rosić G. Alterations of the oxidative status in rat hippocampus and prodepressant effect of chronic testosterone enanthate administration. Mol Cell Biochem. 2017 Mar 24. doi: 10.1007/s11010-017-3014-0. [Epub ahead of print] PubMed PMID: 28342008.
3: Selakovic D, Joksimovic J, Obradovic D, Milovanovic D, Djuric M, Rosic G. The adverse effects of exercise and supraphysiological dose of testosterone-enanthate (TE) on exploratory activity in elevated plus maze (EPM) test - indications for using total exploratory activity (TEA) as a new parameter for ex. Neuro Endocrinol Lett. 2016 Oct;37(5):383-388. PubMed PMID: 28231683.
4: Kaminetsky J, Jaffe JS, Swerdloff RS. Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study. Sex Med. 2015 Sep 17;3(4):269-79. doi: 10.1002/sm2.80. eCollection 2015 Dec. PubMed PMID: 26797061; PubMed Central PMCID: PMC4721027.
5: Bjelic MM, Stojkov NJ, Radovic SM, Baburski AZ, Janjic MM, Kostic TS, Andric SA. Prolonged in vivo administration of testosterone-enanthate, the widely used and abused anabolic androgenic steroid, disturbs prolactin and cAMP signaling in Leydig cells of adult rats. J Steroid Biochem Mol Biol. 2015 May;149:58-69. doi: 10.1016/j.jsbmb.2015.01.012. Epub 2015 Jan 17. PubMed PMID: 25603467.
6: Camozzi V, Bonanni G, Frigo A, Piccolo M, Ferasin S, Zaninotto M, Boscaro M, Luisetto G. Effect of a single injection of testosterone enanthate on 17β estradiol and bone turnover markers in hypogonadal male patients. J Endocrinol Invest. 2015 Apr;38(4):389-97. doi: 10.1007/s40618-014-0183-5. Epub 2014 Oct 16. PubMed PMID: 25319469.
7: Seftel AD. Re: combination therapy of testosterone enanthate and tadalafil on PDE5 inhibitor non-responders with severe and intermediate testosterone deficiency. J Urol. 2013 Feb;189(2):654. doi: 10.1016/j.juro.2012.11.039. Epub 2012 Dec 20. PubMed PMID: 23312193.
Recommended Products
  • CAS No. :151763-89-2
    Product Name:


    Cat No: M098690 View details
  • CAS No. :157733-17-0
    Product Name:


    Cat No: M098693 View details
  • CAS No. :144647-22-3
    Product Name:

    Ethanone, 1-(4-amino-4-methylcyclohexyl)-, trans- (9CI)

    Cat No: M098694 View details
  • CAS No. :153901-53-2
    Product Name:

    6H-(1,2,4)Triazolo(4,3-a)(1,5)benzodiazepine, 8-chloro-5-(4-methyl-1-p iperazinyl)-6-phenyl-

    Cat No: M098695 View details